Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-562-9 | CAS number: 63-68-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Epidemiological data
Administrative data
- Endpoint:
- epidemiological data
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
Data source
Reference
- Title:
- Methionine-loading test: evaluation of adverse effects and safety in an epidemiological study
- Author:
- Krupkova-Meixnerova L, Vesela K, Vıtova A, Janosıkova B, Andel M, Kozich V
- Year:
- 2 002
- Bibliographic source:
- Clin Nutr. 2002;21:151–6.
Materials and methods
Test material
- Reference substance name:
- L-methionine
- EC Number:
- 200-562-9
- EC Name:
- L-methionine
- Cas Number:
- 63-68-3
- Molecular formula:
- C5H11NO2S
- IUPAC Name:
- L-methionine
- Details on test material:
- - Name of test material (as cited in study report): L-methionine
- Supplier: Ajinomoto Co., Inc., Japan;
- Lot/batch No.: five different lots were utilized between 1998 and 2000
Constituent 1
Method
- Details on study design:
- HYPOTHESIS TESTED (if cohort or case control study):
METHOD OF DATA COLLECTION
- Type: Interview / Questionnaire / Record review / Work history / Clinical tests / other:
- Details:
STUDY PERIOD:
SETTING:
STUDY POPULATION
- Total population (Total no. of persons in cohort from which the subjects were drawn):
A total of 296 patients with arteriosclerosis from Prague and central Bohemia were recruited 3 to 6 months after coronarography, acute myocardial infarction,
or ultrasound of peripheral arteries. In addition, 591 controls exhibiting no clinical signs of arteriosclerosis and lacking a personal history of CAD, PAD, or
stroke and coming from the same geographical region took part in the study.
- Selection criteria:
- Total number of subjects participating in study:
- Sex/age/race:
- Smoker/nonsmoker:
- Total number of subjects at end of study:
- Matching criteria:
- Other:
COMPARISON POPULATION
- Type: State registry / Regional registry / National registry / Control or reference group / Other comparison group:
- Details:
HEALTH EFFECTS STUDIED
- Disease(s):
- ICD No.:
- Year of ICD revision:
- Diagnostic procedure:
- Other health effects:
OTHER DESCRIPTIVE INFORMATION ABOUT STUDY: - Statistical methods:
- Categorical variables were counted for each group, proportions were expressed as percents, and the difference in distribution between groups was assessed by the w2 test. The difference in distribution of continuous variables between groups was assessed by the Mann– Whitney rank sum test. Tests were considered significant at P<0.05.
Results and discussion
Any other information on results incl. tables
Acute complications
The major transient complications were dizziness (13%), sleepiness (4%), nausea (3%), and decreased or increased blood pressure (3%). In two individuals, a serious worsening of the overall clinical condition necessitated admission to hospital. It was not possible to determine whether there was a causal relationship between the MLT and the observed clinical problems.
The prevalence of complications was significantly lower in men than in women (16.5% vs 33%, χ2 =30.9, Po0.00001). For each sex, the prevalence of complications in controls was similar to that in patients (15% vs 18% χ2=0.49, P=0.48 for men, and 33% vs 30% χ2=0.20, P=0.65 for women, respectively).
Subacute adverse effects and mortality within a 30-day period after MLT
None of the subjects complained about clinical worsening of pre-existing CAD, PAD, or recurrence of stroke, or novel occurrence of CAD, PAD or stroke within 30 days after the test; in 38 subjects self-reported clinical worsening of arteriosclerosis occurred after this 30-day period. No lethal complications related to the MLT were observed in the one-month interval following methionine loading.
Applicant's summary and conclusion
- Conclusions:
- The methionine-loading test frequently causes transient complications, impairing perception and vigilance, but it does not have serious adverse effects on vasculature and may be considered safe.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.